Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Sidrah Khan, Caroline J. Rieser, Richard S. Hoehn, Samer Tohme, Ibrahim Nassour, David S. Medich, Amer H. Zureikat, Lindsay M. Sabik, Katherine Hrebinko
Publikováno v:
J Surg Res
Background Safety-net hospitals serve a vital role in society by providing care for vulnerable populations. Existing data regarding oncologic outcomes of patients with colon cancer treated at safety-net hospitals are limited and variable. The objecti
Autor:
Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 27:2961-2971
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Brian A. Boone, Joal D. Beane, Mazen S. Zenati, Herbert J. Zeh, A. James Moser, Melissa E. Hogg, David L. Bartlett, Amr I. Al Abbas, Amer H. Zureikat
Publikováno v:
Ann Surg
OBJECTIVES: This study aims to present the outcomes of our decade-long experience of robotic pancreatoduodenectomy and provide insights into successful program implementation. BACKGROUND: Despite significant improvement inmortality over the past 30 y
Autor:
Andrew Lee, James F. Pingpank, Matthew P. Holtzman, Shannon Altpeter, Melanie Ongchin, Caroline J. Rieser, David L Bartlett, M. Haroon A. Choudry, Amer H. Zureikat, Lauren B Hall, Eliza Kang, Heather Jones
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Early recurrence (ER) is a significant challenge for patients with colorectal peritoneal metastases (CRPM) following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS HIPEC). Preoperative risk stratification for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c35eb5532ddc82a4bef8b9c86688e0e8
https://europepmc.org/articles/PMC8666126/
https://europepmc.org/articles/PMC8666126/
Autor:
Deepa Magge, Amer H. Zureikat, Ahmad Hamad, Mazen S. Zenati, Herbert J. Zeh, Melissa E. Hogg, Caroline J. Rieser
Publikováno v:
HPB. 20:1172-1180
NSQIP data show that half of distal pancreatectomies (DP) are performed by a minimally invasive approach (MIS). Advantages have been demonstrated for MIS DP, yet comparative cost data are limited. Outcomes and cost were compared in patients undergoin
Autor:
David S. Medich, Samer Tohme, Katherine Hrebinko, Christof Kaltenmeier, Ibrahim Nassour, Richard S. Hoehn, Amer H. Zureikat, Sidrah Khan
Publikováno v:
Am Surg
Background Colorectal adenocarcinoma is a leading cause of cancer mortality worldwide, often requiring patients to undergo anatomy-altering surgical interventions leading to increased postoperative readmission. Hospital readmission rates have been co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9195409ab701af50771d81c222755ce
https://europepmc.org/articles/PMC8672358/
https://europepmc.org/articles/PMC8672358/
Autor:
Mohamed A. Adam, Amer H. Zureikat, Stacy J. Kowalsky, Ibrahim Nassour, Alessandro Paniccia, Aatur D. Singhi, Nathan Bahary, Kenneth K.W. Lee, Samer Al Masri
Publikováno v:
Journal of surgical oncologyREFERENCES. 123(1)
BACKGROUND There are limited data on the efficacy of neoadjuvant therapy (NAT) for early-stage distal pancreas adenocarcinoma (PDAC). Previous studies focused on adenocarcinoma of the head of the pancreas or dealt with borderline and locally advanced
Autor:
Teng-Kuei Hsu, Christine Decapite, Ofer Shapira, Alessandro Paniccia, Chun Yang, Shivani Mahajan, Richard Bourgon, Peter Ulz, Marvin Bertin, Amit Pasupathy, Julie M. Granka, Adam Drake, C. Jimmy Lin, Tzu-Yu Liu, Preet Kaur, Randall E. Brand, Kaitlyn Coil, Maggie C. Louie, Billie Gould, Hayley Donnella, Amer H. Zureikat, Eric A. Ariazi
Publikováno v:
Cancer Research. 81:PO-007
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with an overall five-year survival rate of 11%. Potential curative resection is possible if the tumor is detected at an early stage, with a five-year survival rate of 42%. The o
Autor:
Caroline J. Rieser, Amer H. Zureikat, James F. Pingpank, Matthew P. Holtzman, David L Bartlett, M. Haroon A. Choudry, Lauren B Hall, Eliza Kang
Publikováno v:
Annals of Surgical Oncology
Background Ninety-day hospital readmission rates following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) range from 20 to 40%. Objective The aim of this study was to develop and validate a simple score to predict rea